LOS ANGELES, May 10, 2023 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of what’s to come May 12, 2023 Deadline for filing a motion by lead plaintiff in the class action lawsuit filed on behalf of investors who have purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”) AMGN common stock in between July 29, 2020 and April 27, 2022inclusive (the “Class Period”).

If you have suffered a loss on your Amgen investments or would like to inquire about potential claims to recover your loss under federal securities laws, you may submit your contact information at www.glancylaw.com/cases/Amgen-Inc/. You can also contact GPM’s Charles H. Linehan at 310-201-9150, toll free at 888-773-9224, or email at shareholders@glancylaw.com to learn more about your rights.

On August 3, 2021, Amgen reported its second quarter 2021 financial results and announced that it had outstanding tax liabilities filed by the IRS and that it received a notice of deficiency from the IRS in July 2021 totaling US$3.1 billion Dollars in back taxes will be required, plus interest for tax years 2010, 2011 and 2012. As a result of this news, Amgen’s share price fell $15.77, or 6.5%, to close on August 4, 2021 at $228.31 per share , which hurt investors.

Then, on April 27, 2022, Amgen issued an earnings statement for the first quarter of 2022 and announced that it had received another deficiency letter from the IRS alleging $5.1 billion in back taxes plus interest for the 2013 tax years , 2014 and 2015 and a proposed $2 billion penalty as a result of the company’s tax avoidance, bringing Amgen’s total amount owed to the IRS in excess of $10 billion. As a result of this news, Amgen’s share price fell $10.66, or 4.3%, to close at $238.13 per share on April 28, 2022, further hurting investors.

The Complaint filed in this Class Action alleges that throughout the Class Period, the Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business,…